Related Experiment Video
Updated: Jul 17, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Interleukin-2 for the treatment of human immunodeficiency virus infection
1Division of Infectious Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA. temesgen.zelalem@mayo.edu
Notwithstanding the significant impact of highly active antiretroviral therapy (HAART) on human immunodeficiency virus (HIV)-associated morbidity and mortality, HAART-induced immune restitution is not complete. The potential utility of interleukin (IL)-2 to augment immune function has been extensively evaluated. Intravenous or subcutaneous IL-2 has been conclusively shown to induce significant increases in CD4 cell counts in HIV-infected patients, in particular when given concomitantly with HAART. Large randomized clinical trials are underway to investigate whether these CD4 cell increments will result in tangible clinical benefits.
Notwithstanding the significant impact of highly active antiretroviral therapy (HAART) on human immunodeficiency virus (HIV)-associated morbidity and mortality, HAART-induced immune restitution is not complete. The potential utility of interleukin (IL)-2 to augment immune function has been extensively evaluated. Intravenous or subcutaneous IL-2 has been conclusively shown to induce significant increases in CD4 cell counts in HIV-infected patients, in particular when given concomitantly with HAART. Large randomized clinical trials are underway to investigate whether these CD4 cell increments will result in tangible clinical benefits.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Sexually Transmitted Infections
Tumor Immunotherapy

